Shopping Cart
- Remove All
Your shopping cart is currently empty
Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD).

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $328 | In Stock | |
| 5 mg | $863 | Backorder | |
| 10 mg | $1,380 | Backorder |
| Description | Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD). |
| Molecular Weight | 149.19KD |
| Cas No. | 347396-82-1 |
| Relative Density. | no data available |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.